Effects of intraduodenal calcium on the release of gut hormone, upper gastrointestinal motility, and energy intake in healthy participants

Christine Feinle-Bisset0 个研究点目标入组 15 人开始时间: 2024年4月30日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Each participant will be questioned prior to the study to exclude:
•significant GI symptoms, disease or surgery
•use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, GI function, body weight or appetite (e.g. domperidone, cisapride, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.)
•lactose intolerance/other food allergy(ies)
•current gallbladder or pancreatic disease
•cardiovascular or respiratory diseases
•individuals with low ferritin levels (females <15 ng/mL, males <30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study
•any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above)
•high performance athletes
•current intake of > 2 standard drinks on > 5 days per week
•current smokers of tobacco (cigarettes, cigars, pipes, sheesha, chewing, vaping etc.)
•recreational drug use, e.g marijuana
•current intake of any illicit substance
•vegetarians
•inability to tolerate nasoduodenal tube
•inability to comprehend study protocol
•restrained eaters (score >12 on the 3-factor eating questionnaire)

发起方